Tokai Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, announced an oral presentation on galeterone at the 2016 American Urological Association (AUA) Annual Meeting in San Diego. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistant prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The presentation, titled “Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2” (abstract number PD32-07), will be presented on Sunday, May 8, from 4:30 - 4:40 p.m. PDT in room 30DE, as part of the session, “Prostate Cancer: Advanced (including Drug Therapy) III.” The presenting author is Vincent C.O. Njar, Ph.D., Professor of Medicinal Chemistry and Pharmacology, Department of Pharmacology; Head of the Medicinal Chemistry Section, Center for Biomolecular Therapeutics; and Member of the Marlene and Stewart Greenebaum Cancer Center at the University of Maryland School of Medicine, Baltimore. Dr. Njar is a co-inventor of galeterone.
Galeterone is an oral small molecule that utilizes the established pathways, including CYP17 enzyme and androgen
receptor inhibition, of the current second-generation hormonal therapies abiraterone and enzalutamide. Galeterone also
introduces a distinct third mechanism – androgen receptor degradation – that decreases the sensitivity of androgen
receptors to androgen activity, thus leading to reductions in tumor growth. Tokai is developing galeterone for the treatment
of patients with metastatic castration-resistant prostate cancer (mCRPC). ARMOR3-SV, the company’s pivotal Phase 3
study of galeterone in treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant, is
evaluating whether administration of galeterone results in a statistically significant increase in radiographic progression-free
survival as compared to enzalutamide. Tokai is also evaluating galeterone in mCRPC patients who have shown resistance
following treatment with second-generation hormonal agents. Tokai has worldwide development and commercialization
rights to galeterone.